[Placebo to antidepressant effects ratio by electroencephalographic data]

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Context:

• Investigated electroencephalogram (EEG) spectral characteristics in patients experiencing mild to moderate depressive episodes.
• Compared placebo effects with monotherapy using antidepressants like fluoxetine and maprotiline.
• Stratified patients into responders and non-responders based on clinical outcomes for both placebo and medication groups.

Purpose:

• To analyze EEG spectral power changes associated with the placebo effect and antidepressant treatment in depression.
• To identify distinct and overlapping EEG alterations between placebo responders and non-responders, and medication responders and non-responders.
• To determine specific EEG markers indicative of a positive therapeutic response to pharmacotherapy.

Summary:

• Placebo administration induced notable changes in EEG spectral power, some mirroring those of a single antidepressant dose, though these effects diminished over the treatment course.
• Significant EEG alterations were predominantly observed in placebo responders.
• Differences in EEG responses between medication responders and non-responders were infrequent, primarily appearing during initial placebo and single-dose antidepressant exposure.
• A characteristic finding for the thymoleptic effect of pharmacotherapy was a shift in the between-hemisphere asymmetry of low-band alpha-rhythm power in frontal regions, signifying increased left-hemisphere activation.

Impact:

• Highlights the neurophysiological impact of the placebo effect in depressive disorders.
• Identifies potential EEG biomarkers for predicting or confirming antidepressant treatment efficacy.
• Provides insights into the neurobiological mechanisms underlying depression treatment, differentiating placebo and drug actions.